MAPT and Alzheimer disease: Targeted removal of senescent cells with the senolytic therapy that has been most comprehensively characterized and studied, combined dasatinib plus quercetin (D+Q), has demonstrated successful reduction of AD-related neuropathological burden of tau-containing neurofibrillary tangles (NFTs)1 and Aß plaques3, and prevented age-associated cognitive deficits in animal models6,7.